BioSig Selects Plexus Corp. as its Manufacturing Partner
September 28 2021 - 9:15AM
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the
“Company”), a medical technology company commercializing an
innovative biomedical signal processing platform designed to
improve signal fidelity and uncover the full range of ECG and
intra-cardiac signals, today announced that the Company entered
into a manufacturing and professional services agreement with
Plexus Corp. [Nasdaq:PLXS].
Headquartered in Neenah, Wisconsin, Plexus Corp. counts
healthcare and life sciences as one of its largest market sectors
representing nearly 40% of annual revenue. Under the terms of the
newly reached agreement, Plexus will bring to market the PURE EP™
System, the Company’s signal processing technology for arrhythmia
care, and develop a new product pipeline for BioSig’s subsidiary
NeuroClear Technologies, Inc.
“We are fundamentally proud to partner with Plexus on our
mission to advance therapies through technological innovation.
Their engineering and manufacturing capabilities and outstanding
expertise in building complex medical devices make Plexus a
foundational cornerstone to support BioSig’s growth objectives now
and well into the future. The recent release of our clinical data
has increased physician interest in our technology. We believe that
the post-pandemic recovery in elective procedures will further
drive our installation footprint, and we are confident that Plexus’
first-class operational infrastructure will ensure a quality supply
of the PURE EP™ systems to meet growing market needs,” commented
Kenneth L. Londoner, Chairman, and CEO of BioSig Technologies,
Inc.
“We are proud to partner with BioSig in helping to bring their
PURE EP™ System to market. The PURE EP™ System is an innovative,
breakthrough device that will greatly improve the healthcare
opportunities for physicians and patients alike. Through this
partnership, we look forward to furthering our vision of helping
create the products that build a better world,” commented Michael
Tendick, Vice President – Healthcare and Life Sciences Market
Sector, Plexus Corp.
The PURE EP™ is an FDA 510(k) cleared non-invasive class II
device that aims to drive procedural efficiency and efficacy in
cardiac electrophysiology. To date, over 60 physicians have
completed over 1300 patient cases with the PURE EP™ System across
twelve clinical sites.
The Company recently completed its first multi-centered,
prospective clinical trial and presented preliminary clinical data
during the annual Heart Rhythm 2021 convention in July in Boston,
MA.
The Company is in a focused commercial launch of the PURE EP™
System in the Northeast, Texas, and Florida and counts some of the
country’s leading centers of excellence, including the Mayo Clinic
in Rochester, MN, and St. David’s Medical Center in Austin, TX,
among its customers.
About Plexus Corp.
Since 1979, Plexus has been partnering with companies to create
the products that build a better world. Plexus has a team of
over 19,000 individuals who are dedicated to providing Design and
Development, Supply Chain Solutions, New Product Introduction,
Manufacturing and Aftermarket Services. Plexus is a global
leader that specializes in serving customers in industries with
highly complex products and demanding regulatory
environments. Plexus delivers customer service excellence to
leading companies by providing innovative, comprehensive solutions
throughout a product’s lifecycle. For more information about
Plexus, visit its website at www.plexus.com. About BioSig
Technologies BioSig Technologies is a medical technology
company commercializing a proprietary biomedical signal processing
platform designed to improve signal fidelity and uncover the
full range of ECG and intra-cardiac
signals (www.biosig.com).
The Company’s first product, PURE EP (tm) System is a
computerized system intended for acquiring, digitizing, amplifying,
filtering, measuring and calculating, displaying, recording and
storing of electrocardiographic and intracardiac signals for
patients undergoing electrophysiology (EP) procedures in an EP
laboratory.
Forward-looking Statements
This press release contains “forward-looking statements.” Such
statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward- looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company’s control, and cannot be predicted or
quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, risks and
uncertainties associated with (i) the geographic, social and
economic impact of COVID-19 on our ability to conduct our business
and raise capital in the future when needed, (ii) our inability to
manufacture our products and product candidates on a commercial
scale on our own, or in collaboration with third parties; (iii)
difficulties in obtaining financing on commercially reasonable
terms; (iv) changes in the size and nature of our competition; (v)
loss of one or more key executives or scientists; and (vi)
difficulties in securing regulatory approval to market our products
and product candidates. More detailed information about the Company
and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company’s filings
with the Securities and Exchange Commission (SEC), including the
Company’s Annual Report on Form 10-K and its Quarterly Reports on
Form 10-Q. Investors and security holders are urged to read these
documents free of charge on the SEC’s website at
http://www.sec.gov. The Company assumes no obligation to publicly
update or revise its forward-looking statements as a result of new
information, future events or otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Jun 2024 to Jul 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Jul 2023 to Jul 2024